Artivion recently announced that it has completed the acquisition of its long-standing partner Endospan, developer of the Nexus aortic arch system.
Artivion shares in a press release that the company utilised its previously drawn US$150 million delayed draw term loan to fund the US$135 million upfront net purchase price for Endospan. The transaction also includes potential additional consideration contingent on commercial performance.
The US Food and Drug Administration (FDA) approved the premarket approval application (PMA) for the Nexus branched endovascular stent graft system in April 2026. Artivion has acted as the exclusive distributor of the Nexus system across Europe, the Middle East and Africa (EMEA) since 2019.
“Our acquisition of Endospan and its Nexus system completes our market-leading, three-pronged aortic arch portfolio. This technology, alongside AMDS and Arcevo LSA, positions us at the forefront of this segment as the only company globally with a complete portfolio of aortic arch solutions,” said Pat Mackin, chairman, president, and CEO. “Further, Nexus is a platform technology, not just a single product. With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time.”
